Physician profile
Patrick Smith
NPI 1417949801
$7,895.98
in general payments reported to CMS, 2019-2025
45 companies · $1,712 in 2025
The $1,712 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,176 · 2022: $2,193 · 2023: $1,605 · 2024: $1,210 · 2025: $1,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,168 · Education: $341 · Debt Forgiveness: $18.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,167.99 |
| Education | $340.63 |
| Debt Forgiveness | $18.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,055.66 | 2021-2025 | |
| Lilly USA, LLC | $627.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $560.26 | 2022-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $477.81 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $369.99 | 2021-2024 | Xarelto |
| Novo Nordisk INC | $363.78 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $328.90 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $297.77 | 2021-2025 | Airsupra, Breztri |
| Shockwave Medical, INC | $196.83 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $189.45 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $185.65 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.64 | 2022-2024 | Jardiance, Tradjenta |
| Pfizer INC. | $157.36 | 2022-2025 | |
| Glaxosmithkline, LLC. | $153.12 | 2021-2023 | Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $148.02 | 2024 | Voquezna |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.